OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Patel on the p53 IHC Positivity as Potential Surrogate for Multi-Hit TP53 Mutations in MDS and AML

July 25th 2025

Shyam A. Patel, MD, PhD, discusses the threshold of p53 IHC positivity best correlating with multi-hit TP53 mutational status in MDS and AML.

Dr Gerber on the Benefits of p53 IHC Testing for Identifying TP53-Mutant MDS and AML in Underserved Regions

July 25th 2025

Jonathan M. Gerber, MD, discusses the potential implementation of p53 IHC testing for MDS and AML in regions with limited access to NGS.

Dr Mewawalla on the Real-World Roles of Cilta-Cel and Ide-Cel in R/R Myeloma

July 24th 2025

Prerna Mewawalla, MD, explains the roles of cilta-cel and ide-cel in clinical practice for the treatment of relapsed/refractory multiple myeloma.

Dr Nieva on the Rationale for Comparing ALK Inhibitors in ALK+ NSCLC

July 24th 2025

Jorge Nieva, MD, discusses matched-adjusted indirect comparison data evaluating crizotinib vs alectinib, brigatinib, and lorlatinib in ALK-positive NSCLC.

Dr Patel on Toxicities Associated With Immunotherapy-Based Combinations in NSCLC

July 23rd 2025

Sandip P. Patel, MD, discusses toxicities associated with the use of immunotherapy-based combination regimens in patients with advanced NSCLC.

Dr McCann on the Standard of Care for Managing ER+/HER2– Advanced Breast Cancer

July 23rd 2025

Kelly E. McCann, MD, PhD, details the current standard of care and novel approaches for the treatment of ER-positive, HER2-negative advanced breast cancer.

Dr Khan on the Role of Zanubrutinib in the Current CLL Treatment Paradigm

July 23rd 2025

Cyrus M. Khan, MD, discusses how zanubrutinib fits into the current treatment paradigm in chronic lymphocytic leukemia.

Dr Kuerer on the Rationale for Eliminating Surgery in Select Patients With HER2+ or Triple-Negative Breast Cancer

July 23rd 2025

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses eliminating surgery for select patients with a pCR after neoadjuvant therapy for early breast cancer.

Dr Shum on Evolving First-Line Treatment Approaches for EGFR-Mutant NSCLC

July 23rd 2025

Elaine Shum, MD, discusses questions that remain regarding the first-line treatment paradigm for patients with EGFR-mutant non–small cell lung cancer.

Dr Donington on the Evolving Use of Perioperative Nivolumab in Resectable NSCLC

July 22nd 2025

Jessica Donington, MD, MSCR, discusses how updated data with perioperative nivolumab in NSCLC may affect future surgical decision-making.

Dr Luminari on the Safety Profile of Odronextamab in Relapsed/Refractory Follicular Lymphoma

July 22nd 2025

Stefano Luminari, MD, details the safety profile of odronextamab for the treatment of patients with relapsed/refractory follicular lymphoma.

Dr McKay on the Safety of Olaparib and Radium-223 in mCRPC With Bone Metastases

July 22nd 2025

Rana R. McKay, MD, FASCO, discusses the safety profiles of olaparib plus radium-223 vs radium-223 monotherapy in mCRPC.

Dr Rutkowski on JPB898 With Ipilimumab in Stage III or Metastatic Stage IV Melanoma

July 22nd 2025

Piotr Rutkowski, MD, discusses a trial evaluating the nivolumab biosimilar JPB898 plus ipilimumab in stage III or metastatic stage IV melanoma.

Dr Komrokji on the Clinical Integration of Imetelstat for Lower-Risk MDSLR-MDS

July 22nd 2025

Rami Komrokji, MD, shares advice on how to integrate imetelstat into clinical practice for transfusion-dependent lower-risk myelodysplastic syndromes.

Dr Pan on Late-Onset Toxicities Associated With CAR T-Cell Therapy in Multiple Myeloma

July 22nd 2025

Darren Pan, MD, outlines late-onset toxicities related to CAR T-cell therapies in multiple myeloma and their management.

Dr Markman on Future Research Directions in Gynecologic Oncology

July 21st 2025

Maurie Markman, MD, discusses future research considerations in gynecologic oncology.

Dr Scarfò on the Future of BGB-16673 in Relapsed/Refractory CLL/SLL

July 21st 2025

Lydia Scarfò, MD, discusses future research directions for BGB-16673 in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Dr Gill on Considering Patients’ Concerns Before Treatment Selection in Advanced CRC

July 21st 2025

Sharlene Gill, MD, MPH, MBA, FRCPC, highlights the importance of considering patients’ concerns ahead of treatment decision-making for advanced CRC.

Dr Hammers on the Efficacy of IO/TKI and IO/IO Regimens in ccRCC

July 18th 2025

Hans Hammers, MD, PhD, discusses the main efficacy differences between IO/TKI and IO/IO combinations in clear-cell renal cell carcinoma.

Dr Rugo on the Safety Profile of Alpelisib in PI3K-Mutant HR+/HER2– Advanced Breast Cancer

July 18th 2025

Hope S. Rugo, MD, discusses the safety profile of alpelisib for the treatment of PI3K-mutant HR-positive/HER2-negative advanced breast cancer.